Product Description: Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis[1][2][3][4][5][6].
Applications: Neuroscience-Neurodegeneration
Formula: C2H5NO2
References: [1]Bannai M, et al. Oral administration of glycine increases extracellular serotonin but not dopamine in the prefrontal cortex of rats. Psychiatry Clin Neurosci. 2011 Mar;65(2):142-9. /[2]Fone KCF, et al. Comparative Pro-cognitive and Neurochemical Profiles of Glycine Modulatory Site Agonists and Glycine Reuptake Inhibitors in the Rat: Potential Relevance to Cognitive Dysfunction and Its Management. Mol Neurobiol. 2020 May;57(5):2144-2166. /[3]Bruns H, et al. Glycine inhibits angiogenesis in colorectal cancer: role of endothelial cells. Amino Acids. 2016 Nov;48(11):2549-2558. /[4]Borges JP, et al. Glycine inhibits NINJ1 membrane clustering to suppress plasma membrane rupture in cell death. Elife. 2022 Dec 5;11:e78609. /[5]Shafiekhani M, et al. Glycine supplementation mitigates lead-induced renal injury in mice. J Exp Pharmacol. 2019 Feb 18;11:15-22. /[6]Johnson JW, et al. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature. 1987 Feb 5-11;325(6104):529-31.
CAS Number: 56-40-6
Molecular Weight: 75.07
Compound Purity: 99.26
Research Area: Neurological Disease
Solubility: H2O : 25 mg/mL (ultrasonic)/Methanol : < 1 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Endogenous Metabolite;iGluR;VEGFR
English
Deutsch
